Evidence map›Paper›PMID 31608175›Full record

ArticlePeerJ2019

MicroRNA-205-5p inhibits three-dimensional spheroid proliferation of ErbB2-overexpressing breast epithelial cells through direct targeting of CLCN3.

Takayoshi Takeno, Takuya Hasegawa, Hiroki Hasegawa, Yasuyuki Ueno, Ryo Hamataka, Aya Nakajima, Junji Okubo, Koji Sato, Toshiyuki Sakamaki

Open access · goldAbstract read
In one paragraph

Article in PeerJ, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. miR-205 in Breast Cancer: State of the Art.International journal of molecular sciences · 2020
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Takayoshi TakenoLaboratory of Public Health, Faculty of Pharmacy, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Niigata, Japan.
Takuya HasegawaLaboratory of Public Health, Faculty of Pharmacy, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Niigata, Japan.
Hiroki HasegawaLaboratory of Public Health, Faculty of Pharmacy, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Niigata, Japan.
Yasuyuki UenoLaboratory of Public Health, Faculty of Pharmacy, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Niigata, Japan.
Ryo HamatakaLaboratory of Public Health, Faculty of Pharmacy, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Niigata, Japan.
Aya NakajimaLaboratory of Public Health, Faculty of Pharmacy, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Niigata, Japan.
Junji OkuboLaboratory of Public Health, Faculty of Pharmacy, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Niigata, Japan.
Koji SatoLaboratory of Public Health, Faculty of Pharmacy, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Niigata, Japan.
Toshiyuki SakamakiLaboratory of Public Health, Faculty of Pharmacy, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Niigata, Japan.
Niigata University of Pharmacy and Applied Life Sciences · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously reported that microRNA-205-5p (miR-205-5p) is significantly decreased in the ErbB2-overexpressing breast epithelial cell line MCF10A-ErbB2 compared with control cells. In this study, we identified a direct target of miR-205-5p, chloride voltage-gated channel 3 (CLCN3). CLCN3 expression was induced by ErbB2 overexpression; this induced expression was then reduced to control levels by the transfection of the miR-205-5p precursor. In RNA-binding protein immunoprecipitation with Ago1/2/3 antibody, CLCN3 was significantly enriched in 293T embryonic kidney cells with miR-205-5p mimic transfection compared with negative control mimic transfection. In luciferase reporter assays using CLCN3 3'-UTR constructs, the miR-205-5p mimic significantly decreased reporter activity of both wild-type and partial mutant constructs in MCF10A-ErbB2 cells. In contrast, no inhibitory effects of the miR-205-5p mimic were detected using the complete mutant constructs. Since miR-205-5p expression in exosomes derived from MCF10A-neo cells was substantially higher than in exosomes derived from MCF10A-ErbB2 cells, we next investigated whether an exosome-mediated miR-205-5p transfer could control CLCN3 expression. To this end, exosomal miR-205-5p derived from MCF10A-neo cells was functionally transferred to MCF10A-ErbB2 cells, which served to decrease the expression of CLCN3. To assess the roles of CLCN3 in breast cancer, we next performed three-dimensional (3D) spheroid proliferation analyses using MCF10A-ErbB2 cells treated with MCF10A-neo-derived exosomes or CLCN3 shRNA stably expressing SKBR3 and MDA-MB-453 breast cancer cells. Our results showed that both treatment with MCF10A-neo-derived exosome and CLCN3 shRNA expression suppressed 3D spheroid proliferation. Collectively, these novel findings suggest that CLCN3 may be a novel direct target of miR-205-5p and this CLCN3/miR-205-5p interaction may serve a pivotal role in regulating breast cancer cellular proliferation under physiological conditions.

Indexed as

Breast cancerCell spheroidCLCN3ErbB2microRNAmiR-205-5p

Identifiers

PMID31608175
PMCPMC6788438
OpenAlexW2979817275

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.